Maartje E. Visser

1.8k citations

13 papers · 939 indexed · h-index 12

Surgery top 10%
Endocrinology, Diabetes and Metabolism top 5%
Cardiology and Cardiovascular Medicine top 5%
Molecular Biology
Cancer Research top 10%

Co-authors: Erik S.G. Stroes John J.P. Kastelein Aart J. Nederveen Geesje M. Dallinga‐Thie Brenda F. Baker Miklós Péterfy Fatima Akdim Diane L. Tribble
Topics: Lipoproteins and Cardiovascular Health (7 papers)Lipid metabolism and disorders (6 papers)Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers)
Cited by: Endocrinology, Diabetes and Metabolism Cardiology and Cardiovascular Medicine Cancer Research
Journals: PLoS ONE European Heart Journal The American Journal of Cardiology
Partner nations: Netherlands United States Belgium

In The Last Decade

Maartje E. Visser

13 papers receiving 917 citations

Peers

Countries citing papers authored by Maartje E. Visser

Since Specialization

Citations

This map shows the geographic impact of Maartje E. Visser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maartje E. Visser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maartje E. Visser more than expected).

Fields of papers citing papers by Maartje E. Visser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maartje E. Visser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maartje E. Visser. The network helps show where Maartje E. Visser may publish in the future.

Co-authorship network of co-authors of Maartje E. Visser

This figure shows the co-authorship network connecting the top 25 collaborators of Maartje E. Visser. A scholar is included among the top collaborators of Maartje E. Visser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maartje E. Visser. Maartje E. Visser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	The Effect of a Diiodothyronine Mimetic on Insulin Sensitivity in Male Cardiometabolic Patients: A Double-Blind Randomized Controlled Trial 2014 ·PLoS ONE ·(unknown),(unknown),Maartje E. Visser,(unknown),(unknown),(unknown),Chaitanya Dutt,Vijay Chauthaiwale,Mariëtte T. Ackermans,Aart J. Nederveen,Mireille J. Serlie,Max Nieuwdorp,Erik S.G. Stroes	28
2	Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial 2012 ·European Heart Journal ·Maartje E. Visser,Gilbert Wagener,Brenda F. Baker,Richard S. Geary,Joanne M. Donovan,Ulrich Beuers,Aart J. Nederveen,Joanne Verheij,Mieke D. Trip,Dick C.G. Basart,John J.P. Kastelein,Erik S.G. Stroes	140
3	Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia 2012 ·Journal of Internal Medicine ·Ramya Preethi Surendran,Maartje E. Visser,Steffie Heemelaar,(unknown),Jorge Peter,Joep C. Defesche,Jan Albert Kuivenhoven,Maryam Hosseini,Miklós Péterfy,John J.P. Kastelein,Christopher T. Johansen,Robert A. Hegele,Erik S.G. Stroes,Geesje M. Dallinga‐Thie	179
4	Antisense oligonucleotides for the treatment of dyslipidaemia 2012 ·European Heart Journal ·Maartje E. Visser,Joseph L. Witztum,Erik S.G. Stroes,John J.P. Kastelein	74
5	APOE1 mutation in a patient with type III hyperlipoproteinaemia: detailed genetic analysis required. 2012 ·PubMed ·Maartje E. Visser,Geesje M. Dallinga‐Thie,Sara‐Joan Pinto‐Sietsma,(unknown),Erik S.G. Stroes,(unknown)	6
6	Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C) 2011 ·Diabetologia ·Maartje E. Visser,(unknown),Mariëtte E.G. Kranendonk,Arianne van Koppen,Nicole Hamers,Erik S.G. Stroes,Eric Kalkhoven,Houshang Monajemi	34
7	Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia 2011 ·Diabetologia ·Maartje E. Visser,(unknown),Aart J. Nederveen,(unknown),Arend Heerschap,Mariëtte T. Ackermans,H. P. Sauerwein,Erik S.G. Stroes,Mireille J. Serlie	49
8	Apolipoprotein B synthesis inhibition: results from clinical trials 2010 ·Current Opinion in Lipidology ·Maartje E. Visser,John J.P. Kastelein,Erik S.G. Stroes	34
9	Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia 2010 ·The American Journal of Cardiology ·Fatima Akdim,Maartje E. Visser,Diane L. Tribble,Brenda F. Baker,Erik S.G. Stroes,Rosie Z. Yu,JoAnn Flaim,John Q. Su,Evan A. Stein,John J.P. Kastelein	141
10	Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study 2009 ·International Journal of Cardiology ·Jamal S. Rana,Maartje E. Visser,Benoît J. Arsenault,Jean‐Pierre Després,Erik S.G. Stroes,John J.P. Kastelein,Nicholas J. Wareham,S. Matthijs Boekholdt,Kay‐Tee Khaw	32
11	The metabolism of triglyceride-rich lipoproteins revisited: New players, new insight 2009 ·Atherosclerosis ·Geesje M. Dallinga‐Thie,Remco Franssen,Hans L. Mooij,Maartje E. Visser,H. Carlijne Hassing,Frank Peelman,John J.P. Kastelein,Miklós Péterfy,Max Nieuwdorp	123
12	Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia 2009 ·Journal of Lipid Research ·Maartje E. Visser,Fatima Akdim,Diane L. Tribble,Aart J. Nederveen,T. Jesse Kwoh,John J.P. Kastelein,Mieke D. Trip,Erik S.G. Stroes	88
13	LDL-C-Lowering therapy: Current and future therapeutic targets 2008 ·Current Cardiology Reports ·Maartje E. Visser,Lily Jakulj,John J.P. Kastelein,Erik S.G. Stroes	11

About Maartje E. Visser

Maartje E. Visser is a scholar working on Endocrinology, Diabetes and Metabolism, Cancer Research and Cardiology and Cardiovascular Medicine, having authored 13 papers that have together received 939 indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (7 papers), Lipid metabolism and disorders (6 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (397 citations), Cardiology and Cardiovascular Medicine (356 citations) and Cancer Research (207 citations). Maartje E. Visser has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Erik S.G. Stroes, John J.P. Kastelein, Aart J. Nederveen, Geesje M. Dallinga‐Thie, Brenda F. Baker, Miklós Péterfy, Fatima Akdim, Diane L. Tribble, Mieke D. Trip and Joseph L. Witztum. Their work appears in journals such as PLoS ONE, European Heart Journal and The American Journal of Cardiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact